ARA-290 (cibinetide)
A small peptide built from erythropoietin (EPO) that keeps EPO’s tissue-protective effect without raising red blood cells.
Investigational (phase 2); not approved.
Used for
- Small-fiber neuropathy and nerve pain
- Neuropathy in diabetes and sarcoidosis
How it works
Activates the “innate repair receptor” (EPO receptor + CD131), which calms inflammation and supports nerve repair.
What the research shows
- In a 28-day phase 2b trial in sarcoidosis nerve loss, 4 mg daily increased small nerve fibers in the cornea and skin; pain improved in all groups including placebo.
- Earlier pilot trials in sarcoidosis and type 2 diabetes reported less neuropathic pain.
Dosing
Dosing isn’t listed on the public site. In the app, each published option is shown with its source (a drug label, a clinical guideline, a trial or community reports) and can be turned into a protocol you review.
Work out the units to draw for your vial →Side effects
- Mild in trials; similar to placebo
Cautions
- Research-chemical vials have no quality control: purity, dose and sterility vary. Third-party testing helps but is no guarantee.
Storage
Unmixed powder: freezer or fridge, away from light.
Once mixed with bacteriostatic water: fridge; the common rule is to use it within 28 days.
There is no label or published stability data for this one, so treat these as habits, not limits.
More in Healing & recovery
Reference only, not medical advice. Written for this app from the cited research. Doses marked community-reported are not from trials.